Saturday 17 October 2026
Export DRTS’s income statement to Excel — free account
Alpha Tau Medical Ltd.
DRTS Healthcare Biotechnology
In the quarter to June 2026, EPS fell 100.0%, free cash flow fell 30.4% and total debt rose 12.8%, each against the same quarter a year earlier.
12.29
0.87
−6.61%
Follow DRTS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
8.43 | 7.45 | 7.79 | 11.09 |
Net Debt/EBITDA |
0.00 | 0.00 | 5.26 | 0.00 | |
Debt/Assets |
5.88% | 6.01% | 5.89% | 5.07% | |
Debt/Equity |
0.08 | 0.08 | 0.09 | 0.15 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
— | — | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | — | (0.45) | |
Interest Coverage |
— | — | (1.38) | — | |
Research and Development Expense of Revenue |
— | — | 0.00% | — | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Free Cash Flow per Share |
— | — | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.85 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.77 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.77 | 0.00 | |
Free Cash Flow |
— | — | — | (1.18) | |
Working Capital |
67.96 | 67.79 | 70.90 | 97.20 | |
Capital Expenditures |
— | — | — | (0.43) | |
Net Current Asset Value |
49.99 | 49.75 | 41.93 | 16.64 | |
| Other line items | |||||
Quick Ratio |
7.90 | 6.96 | 7.31 | 10.45 | |
Revenue per Share |
— | — | 0.00 | — | |
Operating CF per Share |
— | — | 0.00 | 0.00 | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Average Payables |
2.78 | 3.70 | 3.15 | 2.78 | |
Average Assets |
97.71 | 95.93 | 94.85 | 122.60 | |
Average Common Equity |
73.49 | 69.88 | 62.84 | 65.34 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates